Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Toronto

$55,000.00

Reactive Oxygen Species Production by Chemiexcitation

FY 2024-25

Summary
Chemiluminescence (CL) requires no light excitation, making it a useful process to exploit for biomedical research. Most commonly, CL has been used to study cellular function through biomolecular imaging. To a lesser extent has CL been used to drive the activation of drugs. Such a strategy would be powerful, particularly in the field of photodynamic therapy (PDT), whereby chromophores called photosensitizers (PS) require absorption of visible light to produce cytotoxic reactive oxygen species (ROS) to irradicate diseases such as cancer. Due to lights' 1-5 mm tissue penetration depth, the requirement for external irradiation to produce ROS in vivo has posed a major therapeutic limitation to PDT. To overcome this limitation, several groups have used CL to drive production of ROS. However, these systems use intermolecular chemiluminescence resonance energy transfer (CRET) and require the addition of multiple agents, thereby limiting their therapeutic potential in vivo. We recently developed a single, water-soluble compound capable of producing ROS without light excitation. To achieve this, we used a phenoxy-dioxetane, which are stable until removal of a phenoxy protecting group. The resulting phenolate disassembles through an intramolecular electron exchange mechanism to the dioxetane, producing a singlet excited state species. By tethering a PS to the scaffold, CRET occurs, generating a singlet excited PS, which then intersystem crosses to the triplet state producing ROS. Although successful in cells, our compounds low ROS production efficiency of 4% limits its applicability in vivo. We are proposing to explore new chemical designs that use chemiexcitation for the production of ROS with high efficiency. We will achieve this by converting the phenoxy-dioxetane into a PS, thereby bypassing CRET, reducing the number of steps for ROS production. Strategy 1: We will electronically conjugate PSs via vinyl or triazole linkages to various positions on the phenoxy-dioxetane core. We will employ PSs such as diiodo-BODIPY or phenalenone and use ligation chemistries such as Heck coupling or click chemistry. Strategy 2: We will amend the adamantly enolether to a PS that contains a phenoxy or aniline moiety, generating PS-dioxetane chimeras. Using Stille cross-coupling, we will install the dioxetane moiety on PSs that are thionated versions of fluorophores (e.g., thiocoumarin), known to produce ROS via light excitation. Strategy 3: We will install chalcogenophenes (e.g., tellurophene) on the phenoxy-dioxetane core. Phenyl-telluorophenes have photosensitizing properties and so the installation of the adamantly-dioxetane will drive ROS production without the need for large dyes. Once the dioxetanes are synthesized, we will test their degree of CL and ROS production in the dark. The proposed work will overcome the light limitations of PDT, making the treatment more efficacious and expanding its application against a broader range of cancers.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2024-06396
Name nom
Beharry, Andrew
Department département
Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
55000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1202
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Physical sciences
Area of application fr
Sciences physiques
Research subject code
3706
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic photochemistry
Research subject fr
Photochimie organique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Reactive Oxygen Species Production by Chemiexcitation
Keywords
reactive oxygen species; chemiluminescence; phenoxy-dioxetane; photosensitizer
Application summary
Chemiluminescence (CL) requires no light excitation, making it a useful process to exploit for biomedical research. Most commonly, CL has been used to study cellular function through biomolecular imaging. To a lesser extent has CL been used to drive the activation of drugs. Such a strategy would be powerful, particularly in the field of photodynamic therapy (PDT), whereby chromophores called photosensitizers (PS) require absorption of visible light to produce cytotoxic reactive oxygen species (ROS) to irradicate diseases such as cancer. Due to lights' 1-5 mm tissue penetration depth, the requirement for external irradiation to produce ROS in vivo has posed a major therapeutic limitation to PDT. To overcome this limitation, several groups have used CL to drive production of ROS. However, these systems use intermolecular chemiluminescence resonance energy transfer (CRET) and require the addition of multiple agents, thereby limiting their therapeutic potential in vivo. We recently developed a single, water-soluble compound capable of producing ROS without light excitation. To achieve this, we used a phenoxy-dioxetane, which are stable until removal of a phenoxy protecting group. The resulting phenolate disassembles through an intramolecular electron exchange mechanism to the dioxetane, producing a singlet excited state species. By tethering a PS to the scaffold, CRET occurs, generating a singlet excited PS, which then intersystem crosses to the triplet state producing ROS. Although successful in cells, our compounds low ROS production efficiency of 4% limits its applicability in vivo. We are proposing to explore new chemical designs that use chemiexcitation for the production of ROS with high efficiency. We will achieve this by converting the phenoxy-dioxetane into a PS, thereby bypassing CRET, reducing the number of steps for ROS production. Strategy 1: We will electronically conjugate PSs via vinyl or triazole linkages to various positions on the phenoxy-dioxetane core. We will employ PSs such as diiodo-BODIPY or phenalenone and use ligation chemistries such as Heck coupling or click chemistry. Strategy 2: We will amend the adamantly enolether to a PS that contains a phenoxy or aniline moiety, generating PS-dioxetane chimeras. Using Stille cross-coupling, we will install the dioxetane moiety on PSs that are thionated versions of fluorophores (e.g., thiocoumarin), known to produce ROS via light excitation. Strategy 3: We will install chalcogenophenes (e.g., tellurophene) on the phenoxy-dioxetane core. Phenyl-telluorophenes have photosensitizing properties and so the installation of the adamantly-dioxetane will drive ROS production without the need for large dyes. Once the dioxetanes are synthesized, we will test their degree of CL and ROS production in the dark. The proposed work will overcome the light limitations of PDT, making the treatment more efficacious and expanding its application against a broader range of cancers.